查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年生物製藥管的全球市場
市場調查報告書
商品編碼
1272768

2023-2030 年生物製藥管的全球市場

Global Biopharmaceutical Tubing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球生物製藥管市場預計將實現利潤豐厚的增長，到 2022 年將達到 35.804 億美元，到 2030 年將達到 66.742 億美元。 預計在預測期內（2023-2030 年），生物製藥管市場的複合年增長率為 8.3%。 預計在預測期內，鉑固化矽膠管作為一種材料的推出和使用將成為生物製藥調整市場的一個主要趨勢。

因此，玩家有很好的機會以優質且具有成本效益的產品進入生物製藥管材市場。 例如，2020 年 1 月，Watson-Marlow Fluid Technology Group (WMFTG) 推出了 BioPure 矽膠輸送管，它為廣泛的生物過程流體輸送應用提供了安全、可靠且具有成本效益的解決方案。

Bio Pure 矽膠管是半透明且抗撕裂的。 設計用於製藥和生物技術產品的製造過程。 用於製藥和生物技術應用的管材具有一定的規格。 使用可提取化合物時，這些包括承受滅菌過程的能力和傳達陽性測試結果的能力。

由於與其他材料相比具有易滅菌、純度高、柔韌性好、無副作用等諸多優點，矽膠生物藥管的使用率越來越高，受此因素影響，生物藥管市場增速較高。 生物製藥管材市場規模包括矽膠、金屬、塑料等生物製藥管材種類，以及在製藥/生物製藥、臨床、研發等各個領域的應用。

市場動態

人口老齡化和戰略舉措推動生物製藥管材市場增長

隨著人口老齡化的加劇，生物製藥管的全球市場正在擴大。 預期壽命的延長導致世界上老年人口不斷增加。 根據世界衛生組織 (WHO) 的數據，世界 60 歲及以上人口的比例將從 2015 年的 12% 增加到 2050 年的 22%，幾乎翻了一番。

根據聯合國《世界人口老齡化報告》，2017 年全球 60 歲及以上人口有 9.62 億，預計到 2050 年將達到約 21 億。

此外，產品發布、收購、合併和合作夥伴關係等戰略舉措也將為市場帶來利潤豐厚的增長。 例如，2021 年 4 月，再生醫學開發商 BioCardia, Inc. 與日本一家頂級生物技術公司就潛在的 BioCardia Helix 導管生物治療輸送產品達成協議。 這是使用具有特定細胞類型的 BioCardia 螺旋導管進行生物治療藥物心臟輸送的非排他性全球許可。

對於製造商而言，擴大研發和技術突破帶來了巨大的擴張機會。 生物製藥管材越來越多地被製藥和生物製藥行業用於物質和材料的輸送，因此生物製藥管材的市場機會是巨大的。

研發和技術進步為製造商提供了有利的增長前景

生物製藥管材在製藥和生物製藥公司中被廣泛接受用於化合物和材料的運輸，因此存在巨大的市場機會。 對矽膠和金屬生物製藥管等產品的需求將為製造商提供有利可圖的增長選擇。

矽膠管和軟管可用於輸送通常用於生物製藥就地清洗 (CIP) 和 SIP（□□就地滅菌）操作的化學品。 用於製藥和生物製藥應用的管材具有一定的規格。 目前正在研究和開發各種類型的矽膠管，但在此之前，需要滿足醫療領域的使用標準，例如無毒和清潔。

醫用矽膠管必須無臭、無毒、無味。 此外，它不得傾向於促進細菌的生長。 因此，技術進步和不斷增加的研究和開發正在促進市場的增長。

與使用生物製藥管相關的缺點和限制

在加工含有動物成分或動物衍生化合物的產品時，大多數製藥和生物製藥公司都會遇到與動物成分及其對成品影響相關的問題。 管道材料有時會與工業化合物發生反應。

矽油也可能是一種危險材料。 矽油可能會與其他成分發生反應並殘留在產品中。 在製藥和生物技術領域，焊接不良和管內表面是腐蝕和污染的主要原因。

由於管道和管件佔與產品流體接觸表面積的 90%，因此這些部件的製造方式必須能夠輕鬆、一致地進行高質量焊接，以實現無故障製造。我做到了。

有關此報告的更多信息 - 索取樣本

COVID-19 影響分析

除了 COVID-19 前、COVID 和後 COVID 情景外，對 COVID-19 的分析還包括價格動態（大流行期間的價格變化，與 COVID 前情景的比較等）、供需譜（由於限制、封鎖和事後問題導致的供需貿易變化）、政府舉措（政府機構的市場、行業和部門激活舉措）以及製造商的戰略舉措。

俄烏衝突分析

由於該地區的主要市場參與者數量較少，因此估計俄羅斯-烏克蘭衝突對全球生物製藥管市場的影響較小。 不過，原材料進出口的影響預計在預測期內對全球生物製藥管市場的增長影響不大。

內容

第一章調查方法及範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 片段類型
  • 片段：按用途
  • 摘要：按地區

第四章市場動態

  • 影響因素
    • 主持人
      • 不斷增加的老年人口和戰略舉措
      • 一次性系統 (SUS) 應用的擴展
    • 約束因素
      • 與使用生物製藥試管相關的缺點或限制
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 矽膠
  • 塑料
  • 金屬

第 8 章應用

  • 製藥和生物製藥
  • 臨床領域
  • 用於研究和開發
  • 診斷

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第11章公司簡介

  • W. L. Gore and Associates, Inc.
    • 公司概況
    • 產品組合和概述
    • 財務摘要
    • 主要發展狀況
  • DuPont de Nemours, Inc.
  • Freudenberg Group（Freudenberg Medical）
  • REHAU Group（Raumedic AG）
  • Genstar Capital LLC（TekniPlex）
  • Holland Applied Technologies, Inc.
  • Sartorius AG
  • Saint-Gobain
  • Ami Polymer
  • Nordson Corporation

第12章 附錄

簡介目錄
Product Code: MD4254

Market Overview

The global biopharmaceutical tubing market reached US$ 3,580.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,674.2 million by 2030. The biopharmaceutical tubing market is expected to exhibit a CAGR of 8.3% during the forecast period (2023-2030). The launch and use of platinum-cured silicone tubing as a material of choice will likely emerge as a significant trend in the biopharmaceutical tuning market during the forecast period.

Thus, the players have significant opportunities to enter the biopharmaceutical tubing market with superior and cost-effective products. For instance, in January 2020, Watson-Marlow Fluid Technology Group (WMFTG) launched BioPure silicone transfer tubing to confer safe, reliable, and cost-effective solutions for a wide range of bioprocess fluid transfer applications.

Biopharmaceutical tubing is tear-resistant that is translucent. It is designed for use in manufacturing procedures for pharmaceutical and biotechnology products. Tubing utilized in pharmaceutical or biotech applications has certain specifications. When using extractable compounds, the capacity to endure sterilizing procedures and the transmission of positive test results.

The biopharmaceutical tubing market growth rate is high, owing to several factors including the rising adoption of silicone biopharmaceutical tubing due to the number of advantages these have over other materials, such as its ease of sterilization, inherent purity, pliability, and no side effects. The biopharmaceutical tubing market scope includes the type of biopharmaceutical tubing which include silicone, metal, or plastic or the applications of these tubing in various fields such as pharmaceutical and biopharmaceutical, clinical or research and development.

Market Dynamics

The increasing elderly population and strategic initiatives drive the growth of the biopharmaceutical tubing market

The global market for biopharmaceutical tubing is expanding as a result of the rising elderly population. The increase in life expectancy is leading to a rise in the geriatric population in the world. According to the World Health Organization (WHO), the global population share of people with age more than 60 would nearly double from 12% in 2015 to 22% in 2050.

According to the United Nations World Population Ageing Report, in 2017, there were 962 million people with age 60 or above in the world, and the number is expected to reach ~2.1 billion by 2050.

Additionally, strategic initiatives such as product launches, acquisitions, mergers, partnerships, or others will also provide lucrative growth to the market. For instance, in April 2021, concerning the potential of BioCardia Helix catheter biotherapeutics delivery products, BioCardia, Inc., a regenerative medicine developer company, entered into a contract with one of the top Japanese biotechnology firms. It is a non-exclusive, global license for the delivery of biotherapeutics using the BioCardia Helix catheter in particular cell types for cardiac reasons.

For manufacturers, the expanding R&D and technical breakthroughs open very significant expansion opportunities. Biopharmaceutical tubing has a huge biopharmaceutical tubing market opportunity since pharmaceutical and biopharmaceutical industries are increasingly using it to transport their substances or materials.

The growing research and development and technological advancements create lucrative growth prospects for manufacturers

There is a sizable market opportunity for biopharmaceutical tubing, as it is becoming more widely accepted in pharmaceutical and biopharmaceutical companies for the transportation of their compounds or materials. Manufacturers are going to have profitable choices for growth as demand for products like silicone or metal biopharmaceutical tubing will be required.

Silicone tubing and hoses can be used to convey the typical chemicals used in biopharmaceutical CIP (clean-in-place) or SIP (sterilize-in-place) operations. Tubing employed in pharmaceutical as well as biotech applications has certain specifications. The various varieties of silicone tubing are now being researched and developed, but before that can happen, the product must first satisfy the standards for usage in the medical industry, including non-toxicity and cleanliness.

Medical-grade silicone tubing attributes compound compositions that make it odorless, non-toxic, and tasteless. It must not have any tendency that supports bacterial growth. Hence, rising technological advancements or research and development are contributing to the growth of the market.

The disadvantages or limitations associated with the use of biopharmaceutical tubing

When processing products that contain any animal ingredients or compounds derived from animals, the majority of pharmaceutical and biopharmaceutical firms have encountered issues linked to animal ingredients and their possible effects on completed products. Tubing materials can occasionally react with industrial compounds.

Another potentially dangerous material is silicone oils. A residue may be left in the completed product as a result of the oils reacting with other ingredients. Poor welding and inner tube surfaces are the main causes of corrosion/contamination issues in pharmaceutical and biotech operations.

Given that the tubes and fittings make up 90% of the surface area in contact with the product fluid, these parts must be manufactured to make high-quality welding simple and consistent to ensure trouble-free manufacturing.

For more details on this report - Request for Sample

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterwards issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global biopharmaceutical tubing market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global biopharmaceutical tubing market growth over the forecast period.

Segment Analysis

The global biopharmaceutical tubing market is segmented based on type, application and region.

Pharmaceutical and biopharmaceutical segment account for 50.8% of the biopharmaceutical tubing market share, owing to rising demand for tubing in biopharmaceuticals.

The pharmaceutical and biopharmaceutical industry is currently growing due to huge demands owing to the increasing population. Various product launches and formulations are taking place to meet the demand for several products utilizing biopharmaceutical tubing due to its various advantages and characteristics crucial for manufacturing.

Specialized tubing with high quality is crucial for designing an efficient pharmaceutical and biopharmaceutical system for fluid processing. One must take special considerations to avoid possible product contamination found within specific tube composites as residues.

Pharmaceutical and biopharmaceutical manufacturing usually involves batch sample retention and producing drug or substance specimens. These samples (liquid) are continuously stored in small bags with tubing attached. This tubing should be sealed permanently without breaking sterility, using heat and compression to prevent contamination and spillage.

Various key players are developing and launching novel products with the latest innovations. For instance, on May 18, 2022, Freudenberg Medical, a biopharmaceutical and clinical tubing and components manufacturer, introduced its high-purity thermoplastic elastomer tubing HelixFlex, developed for different biopharmaceutical and pharmaceutical applications.

Geographical Analysis

North America holds 40.1% of the market share owing to the strong presence of major players and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for biopharmaceutical tubing for several operations in bioprocessing and storage in North America. The area has many producers and suppliers, and its rapid economic development has increased the industrial production of biopharmaceutical tubing, which has increased the demand.

Growth is also fueled by rising technological advancements and novel product launches. For instance, the AdvantaPURE product portfolio of biopharmaceutical tubing includes various options in its series AdvantaFlex or AdvantaSil. It includes biopharmaceutical pump tubing, platinum-cured silicone tubing and reinforced tubing, and reinforced FEP, PTFE, and EPDM tubing.

AdvantaPURE develops tubing for different needs, such as high-pressure silicone tubing, low-temperature silicone tubing, and tubing specifically developed for the durability of pumping systems and tubing which enhance the pressure capabilities. The aforementioned elements show North America's supremacy on a worldwide scale.

Competitive Landscape

The major global players in the biopharmaceutical tubing market include W. L. Gore and Associates, Inc., Rehu Group (RAUMEDIC AG), Freudenberg Group (Freudenberg Medical), Genstar Capital (Tekni-Plex, Inc.), Holland Applied Technologies, Inc., DuPont de Nemours, Inc., Sartorius AG, Ami Polymer, Saint-Gobain and Nordson Corporation among others.

Why Purchase the Report?

  • To visualize the global biopharmaceutical tubing- market segmentation based on type, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of biopharmaceutical tubing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global biopharmaceutical tubing market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Elderly Population and Strategic Initiatives
      • 4.1.1.2. Growing Application of Single-Use Systems (SUS)
    • 4.1.2. Restraints
      • 4.1.2.1. The Disadvantages or Limitations Associated With the Use of Biopharmaceutical Tubing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Silicone *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Plastic
  • 7.4. Metal

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Pharmaceutical and Biopharmaceutical *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical
  • 8.4. Research and Development
  • 8.5. Diagnosis

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. W. L. Gore and Associates, Inc. *
    • 11.1.1. Company Overview
    • 11.1.2. Type Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. DuPont de Nemours, Inc.
  • 11.3. Freudenberg Group (Freudenberg Medical)
  • 11.4. REHAU Group (Raumedic AG)
  • 11.5. Genstar Capital LLC (TekniPlex)
  • 11.6. Holland Applied Technologies, Inc.
  • 11.7. Sartorius AG
  • 11.8. Saint-Gobain
  • 11.9. Ami Polymer
  • 11.10. Nordson Corporation

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us